Popovits Kimberly J
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.
Transaction History
| KARD | ▲ Buy | Grant | 20,706 | $0 | 6/17/2026 | View on chart |
| TXG | ▲ Buy | Grant | 8,829 | $0 | 6/4/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,799 | — | 5/29/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 18,760 | $290K | 7/30/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 64,508 | $1.9M | 7/30/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 45,748 | $474K | 7/30/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 3,173 | — | 6/5/2025 | View on chart |
| TXG | ▲ Buy | Grant | 15,357 | $0 | 6/3/2025 | View on chart |
| TXG | ▲ Buy | Grant | 8,649 | $0 | 6/11/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 4,373 | — | 6/6/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 5,000 | — | 6/29/2023 | View on chart |
| TXG | ▲ Buy | Grant | 1,865 | $0 | 6/14/2023 | View on chart |
| TXG | ▲ Buy | Grant | 2,120 | $0 | 6/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UBS initiates coverage on Kardigan with $25 price target
UBS has started tracking Kardigan Inc. and set a price target of $25. This new analyst view is notable because it sits below the current average analyst target of $42.25. The stock is currently trading near its support level, which may reflect the mixed sentiment from this new coverage.
UBS initiates coverage on Kardigan with $25 price target. UBS has started tracking Kardigan Inc. and set a price target of $25. This new analyst view is notable because it sits below the current average analyst target of $42.25. The stock is currently trading near its support level, which may reflect the mixed sentiment from this new coverage.